Immunological and virological responses in HIV-1 infected adults at early stage of established infection treated with highly active antiretroviral therapy

AIDS

Volumn 14, Issue 13, 2000, Pages 1887-1897

  Bart, Pierre Alexandre ^a   Rizzardi, G Paolo ^a   Tambussi, Giuseppe ^b   Chave, Jean Philippe ^c   Chapuis, Aude G ^a   Graziosi, Cecilia ^a   Corpataux, Jean Marc ^a   Halkic, Nermin ^a   Meuwly, Jean Yves ^a   Munoz, Miguel ^a   Meylan, Pascal ^a   Spreen, William ^d   McDade, Hugh ^e   Yerly, Sabine ^a   Perrin, Luc ^a   Lazzarin, Adriano ^b   Pantaleo, Giuseppe ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c Clinique de la Source   (Switzerland)

^d GLAXOSMITHKLINE   (United States)

^e University of Geneva ^*

Author keywords

Early established infection; HAART; HIV; HIV specific CD4 cell responses; Immune reconstitution; Lymph node; Plasma viraemia

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; VIRUS RNA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; VIRUS INHIBITION;

ADOLESCENT; ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARBAMATES; CD4 LYMPHOCYTE COUNT; CD4-CD8 RATIO; DIDEOXYNUCLEOSIDES; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LYMPH NODES; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; SULFONAMIDES; VIRAL LOAD;

EID: 0034622945     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200009080-00002     Document Type: Article

References (45)

1. HIV-1 protease inhibitors. A review for clinicians
2. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
3. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team
4. HIV-protease inhibitors
5. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
6. Severe hepatitis in three AIDS patients treated with indinavir
7. Crystalluria and urinary tract abnormalities associated with indinavir
8. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance
9. Treatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort of HIV-1-infected individuals
10. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease
11. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy
12. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
13. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
14. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
15. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
16. Decay characteristics of HIV-1-infected compartments during combination therapy
17. Caution: Should we be treating HIV infection early?
18. Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort Study
19. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir
20. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease
21. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease
22. Lymph node expansion of CD4+ lymphocytes during antiretro-viral therapy
23. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy
24. Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro
25. Abacavir
26. Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89
27. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity
28. Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. Abacavir Phase 2 Clinical Team
29. A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects
30. In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents
31. Lymphoid organs function as major reservoirs for human immunodeficiency virus
32. Sampling lymphoid tissue cells by ultrasound-guided fine needle aspiration of lymph nodes in HIV-infected patients. Swiss HIV Cohort Study
33. The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia
34. Evidence for rapid disappearance of initially expanded HIV-specific CD8+ T cell clones during primary infection
35. Application of branched DNA signal deficiency virus type 1 burden in human plasma
36. Detection of low HIV-1 RNA levels in plasma
37. Effect of immunization with an inactivated gp120-depleted HIV-1 immunogen on beta-chemokine and cytokine production in subjects with HIV-1 infection
38. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia
39. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
40. Can HIV be eradicated?
41. Viral dynamics in HIV-1 infection
42. Limited CD4+ T-cell renewal in early HIV-1 infection: Effect of highly active antiretroviral therapy
43. Changes in thymic function with age and during the treatment of HIV infection
44. HIV-1-speciflc CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression